semaglutide aion Risk of NAION Higher in Patients on GLP-1 Drugs for Diabetes or Weight Loss Semaglutide and Nonarteritic Anterior Ischemic

In TRIUMPH-4, nausea affected around 43% of participants on 12 mg, vomiting 21%, and diarrhoea 33%

A systematic review published in Diabetes, Obesity and Metabolism examined lean body mass changes across GLP-1 based therapies

Some of them openly admitted that they used Ozempic knowingly or without their knowledge of the side effects of the drug

Within the emerging geroscience paradigm 2 , pharmacologic agents originally developed for metabolic indications, such as GLP-1 receptor agonists 3,4,5,6 , have garnered attention due to their potential dual roles in metabolic regulation and aging biology 7

Duration follows the four to six week protocol outlined above

Clarifying this distinction early prevents wasted appointments and manages expectations properly